摘要
目的:探讨急性心肌梗死(AMI)患者基质金属蛋白酶-9(MMP-9)的变化及与心室重构的相关性,并观察缬沙坦对其干预的效果。方法:选AMI患者90例,随机分为常规治疗组和缬沙坦组,正常体检者45例为正常对照组,AMI患者于入选时检测MMP-9,测定超声心动图指标[左室收缩末期容积(LVESV)、舒张末期容积(LVEDV)和左室射血分数(LVEF)],服药1周、4周、12周后再测定MMP-9、超声心动图指标,正常对照组病例入选后测定MMP-9。比较各组病例MMP-9值;比较两治疗组患者用药1周及4周后MMP-9值、用药4周及12周后超声心动图指标及其变化。结果:AMI患者与正常对照组MMP-9值、超声心动图指标比较,差异有统计学意义(P<0.05);用药1周时B组较A组MMP-9值减小(P<0.05);用药4周时A、B两组MMP-9值均减小,而超声心动图指标差异无统计学意义,12周后A、B两组超声心动图指标发生变化(P<0.05);用药1周后、4周后两组MMP-9值均较用药前减小(P<0.05)。结论:缬沙坦能降低AMI患者MMP-9的表达,降低心室重构发生率。
AIM： To observe the changes of plasma MMP-9 in acute myocardial infarction （AMI） patieats and the effect of valsartan on MMP-9. METHODS ： Ninety AMI patients and 45 control cases were recruiled. The patients were randomh divided into two groups： group A （routine treatment group, n =45） and group B （valsartan treatment group, n = 45）. Plasma MMP-9 and echocardiographic indices were measured in all groups and MMP-9 and echocardiographic indices were measured in patient groups at 1 week, 4 weeks and 12 weeks after treatment. RESULTS： No statistical differenee was observed in MMP-9 arid echoeardiographic indices betwet：n groups （P 〉 0.05）. MMP-9 in group A was statistically lower than in group hl I week post-treatment. After 4 weeks, MMP-9 returned to normal in both groups and no statistical difference was found in echocardiographic indices between groups. Twelve weeks after treatment, changes were found in echocardiographic indices in both groups. CONCLUSION： Valsartan reduces the expression of MMP-9 and degrades the incidence of ventricular remodeling in AMI patients.
出处
《心脏杂志》
CAS
2010年第5期727-729,共3页
Chinese Heart Journal
基金
包头市科技计划项目(2008192001-3)
关键词
心肌梗死
急性
基质金属蛋白酶
缬沙坦
myocardial infarction, acute
matrix metatloproteinase-9
valsartan
